drugset / Trial / NCT00644293

A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin Sustained Release Versus 3-Day Azithromycin for the Treatment of Strep Throat in Adolescents and Adults

NCT00644293

Phase 3 Completed 598 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if a single 2.0-g dose of azithromycin SR is at least as effective as a 3-day course of azithromycin (500 mg once daily for 3 days) when used to treat adolescents and adults with strep throat, and to assess efficacy and safety for both treatment regimens.

Timeline

Start
2003-01
Primary completion
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 500 mg Oral
Subject Azithromycin Small molecule 2 g Oral

Indications